German is trying to prevent the United States from coaxing a German company that is currently in the process of developing a coronavirus vaccine to shift its research work to the America. This development has resulted in German politicians stressing that there should not be monopoly of any one country over any future coronavirus vaccine that is developed.
According to reports quoting sources from the German government, efforts were made by the US administration about gaining access to a possible vaccine for the novel coronavirus that is currently being developed by the German firm CureVac.
Fund has been offered earlier to CureVac by the US president Donald Trump to coax the company to shift its research to the United States, claimed an earlier report by the Welt am Sonntag German newspaper. It also stated that counter offers were also being made by the German government to entice it to stay back in the country.
"The Welt story was wrong," tweeted the US ambassador to Germany, Richard Grenell, in response to the report.
"This story is wildly overplayed ... We will continue to talk to any company that claims to be able to help. And any solution found would be shared with the world," a US official was quoted in subsequent reports as saying.
“The German government is very interested in ensuring that vaccines and active substances against the new coronavirus are also developed in Germany and Europe,” said a German Health Ministry spokeswoman while also confirming a quote in the newspaper report published earlier.
"In this regard, the government is in intensive exchange with the company CureVac," she added.
The aim of Trump was to make sure that the scientists of the company working on a possible vaccine works exclusively, according to an unidentified German government source who was quoted in the Welt am Sonntag report. The source also said that the US was willing to go to any lengths to get a vaccine developed not only for the United States, "but only for the United States."
The CureVac case was also discussed by the German government’s coronavirus crisis committee.
"The company rejects current rumours of an acquisition", said CureVac a statement issued by it on Sunday.
Dietmar Hopp, the main investor of CureVac, said that he would not be selling off its shares and added that he wanted the company to be able to develop a vaccine for the novel coronavirus that would "help people not just regionally but in solidarity across the world."
"I would be glad if this could be achieved through my long-term investments out of Germany," he added.
Berlin "has a great interest" in producing vaccines in Germany and Europe, a German Economy Ministry spokeswoman was quoted in various reports about the issue as saying. Berlin could make use of its foreign trade law which would give the German government the power to review rake over bids of companies in of the country by any non-EU company ort the so-called third countries "if national or European security interests are at stake", the spokeswoman was reported as saying,
(Source:www.indiatoday.com)
According to reports quoting sources from the German government, efforts were made by the US administration about gaining access to a possible vaccine for the novel coronavirus that is currently being developed by the German firm CureVac.
Fund has been offered earlier to CureVac by the US president Donald Trump to coax the company to shift its research to the United States, claimed an earlier report by the Welt am Sonntag German newspaper. It also stated that counter offers were also being made by the German government to entice it to stay back in the country.
"The Welt story was wrong," tweeted the US ambassador to Germany, Richard Grenell, in response to the report.
"This story is wildly overplayed ... We will continue to talk to any company that claims to be able to help. And any solution found would be shared with the world," a US official was quoted in subsequent reports as saying.
“The German government is very interested in ensuring that vaccines and active substances against the new coronavirus are also developed in Germany and Europe,” said a German Health Ministry spokeswoman while also confirming a quote in the newspaper report published earlier.
"In this regard, the government is in intensive exchange with the company CureVac," she added.
The aim of Trump was to make sure that the scientists of the company working on a possible vaccine works exclusively, according to an unidentified German government source who was quoted in the Welt am Sonntag report. The source also said that the US was willing to go to any lengths to get a vaccine developed not only for the United States, "but only for the United States."
The CureVac case was also discussed by the German government’s coronavirus crisis committee.
"The company rejects current rumours of an acquisition", said CureVac a statement issued by it on Sunday.
Dietmar Hopp, the main investor of CureVac, said that he would not be selling off its shares and added that he wanted the company to be able to develop a vaccine for the novel coronavirus that would "help people not just regionally but in solidarity across the world."
"I would be glad if this could be achieved through my long-term investments out of Germany," he added.
Berlin "has a great interest" in producing vaccines in Germany and Europe, a German Economy Ministry spokeswoman was quoted in various reports about the issue as saying. Berlin could make use of its foreign trade law which would give the German government the power to review rake over bids of companies in of the country by any non-EU company ort the so-called third countries "if national or European security interests are at stake", the spokeswoman was reported as saying,
(Source:www.indiatoday.com)
Homepage
Send to a friend
Printable version
Share
